



January 1 – December 31, 2025


Annual Report

Promimic AB (publ)

Content

CEO Comments	4
About Promimic.....	6
Customer news.....	9
Innovation	11
Strategy	12
Board and management	14
Management Report.....	17
Financial Reports.....	22
Notes.....	28
Signatures	34
Auditor's Report	35
Corporate Governance Report	38





6 new customers

**20 new
approved products**

Updated long-term goals

**10 years of
clinical use**



Magnus Larsson
CEO, Promimic

Investments for growth

The most important thing to highlight for 2025 is that we have signed six new customer agreements during the year, which is a milestone. Sales for the full year amounted to 44.4 MSEK. Compared to 2024, growth was +1 percent for 2025, when accounting for currency effects, revenue grew by +10 percent. This shows that we continue our growth journey.

Six new customer agreements is a record in itself. This is a record number of customer partnerships in a calendar year. This is not reflected in our 2025 revenue, but through focused sales efforts during the year, we have laid the foundation to take several important steps forward on our growth journey during 2026 and 2027. Among our existing customers, ATEC Spine, Curiteva, and S.I.N. Implant System stand out. Read more about their development during the year on page [9](#).

To ensure continued business expansion and create conditions for future growth, we have expanded our capacity in the US through a new processing facility. Through this expansion, we have tripled our capacity and secured our future growth.

During the year, we reached several important milestones in the company's development. At year-end, we could confirm that there are now over 2.6 million implants with our HA^{nano} Surface in clinical use. 23 percent of these implants were sold during the last year, indicating our growth in the clinical usage of our technology is on a growth trajectory

We could also celebrate a 10-year anniversary at the end of last year. It was on December 14, 2015, that our Brazilian customer S.I.N. Implant System received their first approval to start selling dental implants with HA^{nano} Surface. They were well-prepared and launched their new implant system immediately. HA^{nano} Surface today serves as their premium version for all their implants and has been an important piece in their growth journey, to now being one of two market leaders in Brazil with growing sales in the US, Europe, the Middle East, and India.

The benefit of our technology has also been confirmed during the year by FDA approving several of our customers' products. Two of them have achieved a special market position through a *Nano Technology Designation* from the FDA. Among our customers, ATEC Spine and Curiteva are the first in this category. We are working to facilitate additional customers to follow in obtaining *Nano Technology Designation*, which in many cases has allowed for a special category for obtaining higher reimbursement and pricing.

We have strengthened our organization in the US by moving technical competence to our office in Austin, Texas. This provides a higher service level, and we can support our customers on-site instead of remotely from Sweden. The strengthening will also benefit our process company NPI in its work to develop the business.

During the year, we have continued our investment in being able to coat suture materials with our HA^{nano} Surface. In two pre-clinical studies, together with the

research institute RISE, we have shown improved cell activity and bone integration for sutures with our surface. This opens up new opportunities for surface treatment of suture anchors in sports medicine treatments. Suture anchors are used to attach ligaments and tendons in shoulders, knees, and ankles in various types of sports injuries.

With this step into the sports medicine market, we are now active in the three major sub-segments within orthopedics: Large Joints (hip/knee implants), Spine (spinal implants), and Sports Medicine, as well as the Dental Implant Market.

Our goal is to achieve an average annual growth (CAGR) of over 25 percent per year, given a fixed exchange rate. This will fluctuate from quarter to quarter, as we saw in 2025, but the use of our HA^{nano} Surface on the international implant market continues to grow. The number of patients receiving better implant treatments thanks to our implant surface is constantly increasing. That both the number of customers and clinical usage continue to grow, and that customers are launching new implants on the market, is our growth engine.

The global situation continues to be uncertain, but I want to be clear that tariffs do not have a major impact on Promimic's revenues. However, Promimic's business model is not affected to any major degree by tariffs and duties. Our operations in our subsidiary Nano Processing Inc. (NPI) are not affected at all. The only product we export to the US is our coating liquid, and it is affected by tariffs, but it is a smaller part of our total business.

In the coming years we expect to reduce the percentage of investments when compared to revenue and further capitalize on our investments to date. Our short-term goal is to be cash


positive and profitable while continuing to grow and reinvest in our business model. Our development of an antibacterial surface continues. We have made progress during the year that we are now taking to the next step in the development. The development builds on our existing HA^{nano} Surface, our goal being to develop a surface modification that both stimulates integration and is antibacterial.

I am proud of how the team focuses on our priority areas and drives our projects so that we can reach our goals. Together we have built a platform for continued expansion and growth for Promimic.


Mölnådal, April 9, 2026

Magnus Larsson
CEO, Promimic

Implants in clinical use



Net sales, rolling 12 months (MSEK)



About Promimic

Background

Promimic has developed a state-of-the-art nanotechnology that mimics nature, making it possible to create a unique bioactive surface on any implant. The company manufactures, markets and sells these biomaterials for improved osseointegration (bone healing) to leading companies in the dental, spine, total joint, extremities, and sports medicine implant markets. Promimic is headquartered in Mölndal, Sweden with sales offices in USA. The processing of implants is done through the joint venture, Nano Processing Inc. in Indiana, USA. With over 2,600,000 implants in clinical use worldwide, the company's technology is accepted and ready for growth with both established partners and new customers.

Products and market

The company's technology platform is a new generation of nanometer-thin surface modification of the outermost layer of the implant. The company's main product is HA^{nano} Surface, which causes the surface of the implants to mimic bone crystals, which facilitates the healing process and improves the anchoring of the implants in the bone tissue. This is verified in over 30 clinical and pre-clinical scientific studies.


HA^{nano} Surface was launched in 2015 on dental implants in Brazil as the first market. On December 5, 2017, the first implant with HA^{nano} Surface was cleared by the Food and Drug Administration (FDA) in the United States. That clearance opened up the American market for HA^{nano} Surface and today the surface is used clinically on implants for spine surgery, orthopedics after cancer treatments, implants for closure of the sternum after heart surgery and knee implants.

The technology can be applied to all types of implants that must be anchored in bone. It can also be used on 3D-printed implants, where other traditional technologies do not work. The technology receives regulatory market clearance via a simplified 510(k) process in the United States.


Promimic currently has license agreements with 24 implant companies, of which twelve companies have implants in clinical use. Promimic has established its own sales operation in the USA and secured several partnerships for continued growth and increased commercialization rate.

The implant industry is a large and growing global market with high profit margins. Within the market for orthopedic implants there is currently a growing trend towards uncemented and osseointegrating implants. Especially in the market segments for knee and spinal implants, the trends are currently very favorable for Promimic. With a robust and strategic partnership firmly established in the dental implant market, alongside favorable trends in the orthopedic implant sector, a solid foundation exists for the emergence of numerous new business opportunities that can significantly propel the company's growth trajectory forward.

As the technology is well documented with proven clinical benefit, Promimic sees an opportunity to establish HA^{nano}



 HA^{nano} Surface



Surface as the industry standard in bone-integrated implants.

Business model

Promimic has a license-based business model based on long-term partnerships with market-leading implant manufacturers. The company's revenue structure is a license agreement with milestone-based revenue during the development period and royalty-based revenue when the finished implant is sold to the end customer. The terms of these contracts are long-term and based on a close partnership.

In 2022, Promimic broadened the business model with a step into the process side. Together with Danco Medical, Nano Processing Inc. was formed. The collaboration provides increased growth and profitability through revenue from the coating process of implants in the American market.

It should be noted that according to agreements with our customers, Promimic receives royalty reports 45 days after the end of the quarter. Due to this, Promimic publishes interim reports late in the cycle.


Organization


The team at Promimic has a solid background in sales, business development, financing and marketing towards the orthopedic and dental implant markets. The technical team has a unique technical competence with focus on material chemistry and nano-materials.

Team development within the "One Promimic Team" project has continued to be a high priority in 2025 in order to be able to meet and manage the high growth rate. The "One Promimic

Team" project started with the aim to build a common set of values. The goal is to organize the company's various activities so that they are customer-driven with effective collaborations. Promimic has a culture of letting employees grow with the company and internal recruitment has been high in recent years.

At the end of 2025, there were 18 people employed, 15 employees at the head office in Mölndal, Sweden and three people at the sales office in Austin, Texas in the USA. Nano Processing Inc. employs four people who work with coating our customers' implants for the American market.





Implants in clinical use

1. Dental implants
2. Implants for rigid surgery of the cervical spine: CIF, Stand-alone CIF and fixation screws
3. Implants for fixation of the sternum
4. Different implants for lumbar spine surgery: ALIF, TLIF, LLIF, Stand-alone ALIF
5. Implants for fusion of the Sacroiliac joint
6. Implants for "Limb salvage" after cancer treatment
7. Knee prostheses

Customers and foundation for growth

Promimic has licensed HA^{nano} Surface to customers in both the orthopedic and dental implant markets. The technology can be used on all types of implants that are anchored in bone. The skeleton on the left gives a good overview of the areas of the body where the technology is currently in clinical use.

The first customer to bring HA^{nano} Surface to market for improved osseointegration was S.I.N. Implant System from Brazil. They have halved the healing time of their implants with the help of Promimic's surface and have also been one of the fastest growing companies on the market for dental implants in the past year. This positive progress led S.I.N. in July 2023 to be acquired by the Fortune 500 company Henry Schein, a world-leading dental company.


The major growth today is primarily within the market segment for spinal surgery. There, ATEC Spine is the fastest growing company with a growth of 25 percent for the full year 2025. Promimic is working on developing the collaboration with ATEC Spine to include more implants. Other customers with implants in clinical use in this market segment are Curiteva, Cutting Edge Spine and Innovasis with implants for fusion operations of the SI joint and lumbar spine.

Another fast grower is Able Medical with implants for fixation of the sternum after open heart surgery. Here HA^{nano} Surface is used to create faster healing

and stronger fixation. To date, more than 10,000 patients have been treated.

Our customer, Onkos Surgical, uses Promimic's technology on implants to replace bone after skeletal oncology. Many of Promimic's customers have launched their implants in recent years. In addition, Promimic has several customers who intend to use HA^{nano} Surface as a platform technology, which provides a stable foundation for continued future growth. This is clearly visible in the graph showing the relationship between the number of license agreements and implants in clinical use. This shows that Promimic is currently in the middle of its market and clinical breakthrough and, moreover, the company has a stable foundation for continued growth in the coming years.

Clinical and commercial breakthrough



Customer news

ATEC Spine - Growth rocket

Our largest partner ATEC Spine delivered a strong 2025. ATEC Spine utilizes the HA^{nano} Surface as a platform technology for their spinal implants under the Trademarked name NanoTec. Last year, Promimic collaborated with ATEC Spine to deliver new expandable spinal implants with NanoTec. The new expandable technology is a crucial factor in delivering a more patient personalized implant. Market growth rate for these specific implants is very high, and they are an important part of ATEC Spine growth rate of 25 percent, during calendar year 2025, compared to the average growth for the industry, around four percent. That they continue to deliver growth figures at this level is incredibly impressive.

The implants with NanoTec were approved in 2025 under FDA's new classification, *Nanotechnology Designation*, thanks to ATEC Spine use of HA^{nano} Surface. This classification allows partners of Promimic to state "the implant uses nanotechnology to improve biologic response". ATEC Spine has presented cell studies showing significantly higher cell activity for samples of NanoTec line compared to an untreated titanium surface. This can help the customer achieve a higher price.

Curiteva - Bonded by Innovation

Promimic and Curiteva extended their exclusive licensing agreement in early 2025 for coating 3D-printed Trabecular PEEK implants with HA^{nano} Surface, and the collaboration deepens on multiple levels.

"A partnership with Promimic represents much more than technological progress. We have a shared vision, driven by innovation to offer patients improved care. We create solutions that have the potential to revolutionize implant treatment across many market segments," says Chad Falciani, founder and chairman of the board for Curiteva.

During 2025, Curiteva launched a complete family of new implants with HA^{nano} Surface for spinal surgery, the Lumbar Inspire Portfolio. These are implants utilized in spinal fusion surgery using their unique 3D-printed PEEK production technology. The launch includes both implants with integrated fixation technology and traditional plates and screw fixation.

In connection with the launch, Curiteva announced they had sold 7,300 implants for clinical use. Clinical follow-up conducted shows good integration between the implant and surrounding bone.

S.I.N. Implant System - international expansion

Brazilian S.I.N. Implant System was Promimic's first customer to start selling dental implants. It was exactly 10 years ago that their implants were approved for clinical use. During these 10 years, over 2 million dental implants have been sold for clinical use.

For S.I.N. Implant System, 2025 has been about continued international expansion. They continue to grow on their home markets in South America while their focus on the US remains successful, and they have received regulatory approval to start selling implants in Canada. They have secured an experienced distributor on the Indian market and continue their efforts in Eastern Europe and Turkey.

During the fall, Promimic has worked together with the team at S.I.N. Implant System in Brazil to get their new dental implant Versalis with HA^{nano} Surface into production. The new implant was approved by the FDA for clinical use on the American market during the year.

S.I.N. Implant System has published several scientific articles during the year showing that their implants with HA^{nano} Surface have a significant improvement in cell activity and that the implants integrate faster with bone tissue.



Customer news

Spineology received FDA approval for its 510(k) application for its new implant, OptiMesh HA Nano, on December 15, and even before Christmas the first patients had already been treated.

“By adding HA Nano technology to our OptiMesh implant portfolio, we demonstrate our continued focus on innovation in the field of patient-specific implants,” says Brian Snider, CEO of Spineology.

The market for spinal surgery implants is completely dominated by rigid implants made of titanium, PEEK, or stainless steel. Since its inception, Spineology has challenged this standard with its unique PET-based implant—essentially the same plastic used in beverage bottles, but with much higher purity and medical-grade classification.

The technology is based on using PET fibers woven into an implant that resembles a balloon and can adapt to the patient’s anatomy during spinal fusion procedures. Thanks to Promimic’s unique method, these fibers can now be coated with synthetic bone crystals, giving the implant a bioactive surface that improves integration between the implant and the vertebrae.

Each year, up to 700,000 spinal fusion procedures are performed in the United States, and the implant market is estimated to exceed USD 7 billion. It is expected to continue growing at an annual rate of 4–6 percent over the coming decade. It is in this market that a “new” Spineology is now embarking on its growth journey. Challenging established practice with a new technology is not an easy path. Spineology’s De Novo application received FDA clearance in 2021, and the product has since been improved through new generations of OptiMesh implants. In addition, the company has gained

new investors and, since 2024, a new management team with extensive experience in building fast-growing companies in the spinal implant market.

“Our launch of OptiMesh HA Nano is a unique solution that integrates a well-documented surface technology optimized to enhance osseointegration with an implant that adapts to the individual patient’s anatomy,” continues Brian Snider.

The collaboration between Promimic and Spineology has been ongoing for the past two years. A new method for coating PET implants has been developed, followed by extensive testing to ensure that the nano-thin surface does not detach when the implant is implanted and expanded. This is possible thanks to Promimic’s unique method based on individual nanocrystals, meaning that even if the implant’s macrostructure changes, the nanostructure beneath the crystals remains unaffected.

To support the regulatory process, Promimic has submitted several supplements to its Master File registered with the FDA during this period. This regulatory approval from the FDA means that Promimic can now expand its market to also include fiber-based medical devices that require enhanced osseointegration.

Our launch of OptiMesh HA Nano is a unique solution



Brian Snider
CEO, Spineology

Innovation driving expansion

During the year, Promimic has broadened its customer offering to now include a new coating method at lower temperatures. The focus is on implants within the sports medicine market, which is the fastest growing segment of the implant industry.

This opens up opportunities to apply our HA^{nano} Surface to new types of implants manufactured from various polymers. These implants are thereby given a bioactive surface, creating the conditions for integration between the implant and the surrounding tissue.

The new coating method has been developed following interest from customers in both the United States and Brazil. Listening to customers and driving development where there is clear customer value is a key part of the company's growth strategy. The innovation and technical validation underlying this updated method are prerequisites for customers to obtain regulatory approval for clinical use of their implants. Consequently, Promimic has updated its Master File registered with the U.S. Food and Drug Administration (FDA) with a new technical file.

During 2025, Promimic conducted two preclinical studies together with the research institute RISE to demonstrate the benefits of creating bioactive implants from soft polymers such as PET and UHMWPE, where HA^{nano} Surface enables natural integration of materials that are otherwise inert in the body.

"Our studies show a very strong tissue response for both bone and soft tissue. We see both higher cellular activity and true integration between the tissue and these polymers after treatment with our HA^{nano} Surface," says Per Kjellin, CTO of Promimic.

The results will be published in 2026 and will form an important part of the marketing of HA^{nano} Surface for new market segments.

One of the major advantages of manufacturing implants from soft polymers is their ability to conform to the patient's anatomy. The first customer to bring this new method into clinical use is Spineology, for its OptiMesh HA Nano implants made from the polymer PET, which are used in spinal fusion procedures. Read more on page [10](#).

"Spineology's unique implants truly challenge established methods through their choice of material, which enables minimally invasive surgery. It will now be exciting to follow their growth," says Ulf Brogren, CCO of Promimic.

With growth rates of around seven percent, the sports medicine implant market is one of the fastest-growing areas within the implant industry. Over the past five years, the use of permanent suture anchors made from the polymer UHMWPE in shoulder, knee, and ankle surgery has grown exponentially. Where surgeons previously used titanium or PEEK screws to fix tendons and ligaments, sutures with an expandable anchoring component that is secured inside the bone (with a function similar to a Molly bolt) are now used instead. This new method saves significant time for the surgeon, and for the patient the procedure is less invasive, reducing the risk of complications.

"Over the coming years, we will continue to work methodically to identify and capitalize on the new business opportunities enabled by our new method. We continue our journey as pioneers in using nanotechnology to improve implant treatments," concludes Ulf Brogren.



Updated financial goals

A few years have passed since our initial public offering, and we see this as an opportunity to review our objectives. Both our external environment and our business have evolved. In order to meet the needs of some of our customers, we have also developed our business model.

Business model

At the request of a few customers, we have developed our business model so that we charge already when implants are processed by our U.S. joint venture, NPI. This change means that for these customers we no longer need to wait for future royalty income, as these revenues are instead invoiced directly. As a result, going forward we will consolidate all revenue from royalties, license fees, and processing of customer implants. This change will also improve our cash flow.

Long-term growth and profitability goals

In the autumn of 2021, Promimic prepared for a listing on Nasdaq First North Growth Market. At that time, we established strategic objectives that we considered reasonable and achievable. Initially, we exceeded our own expectations and experienced very strong growth. However, as we did not fully onboard new customers at the pace anticipated during 2023 and 2024, our growth in 2025 was weaker than expected. We have therefore

updated our strategic objectives in both the short and long term to better reflect reality. As reported in this report, we are now back on track with at least four new customer agreements per year, which we view as the foundation for continued strong growth.

We are pleased to inform we have returned to a high level of market activity and have signed six new customer agreements during 2025. These customers will contribute to continued growth, albeit with some delay compared to the original plan. We have also increased our investments in new development projects in order to establish ourselves in new market segments.

Uncertainty in our external environment has increased dramatically, affecting both our outlook and that of our customers. Underlying market growth has temporarily slowed, political uncertainty is a reality in the United States, and the U.S. dollar has weakened against the Swedish krona. The United States is Promimic's most important market, and we are affected when market conditions change.

Going forward, Promimic will provide guidance on future growth and profitability, but will not issue forecasts. The company's target is to grow at a compound annual growth rate (CAGR) exceeding 25 percent. In comparison, the relevant markets in which we operate are expected to grow at approximately five percent, meaning that we plan to grow five times the average market growth rate. Our long-term goal is also to achieve an EBITDA margin exceeding 40 percent.



Strategy and long-term goals

Vision

World leader in using nano-technology to improve clinical outcomes in implant surgery.

Mission

Through partnership with a growing group of internationally leading medical technology companies sell technologies for surface modifications of implants that create clear clinical and commercial benefit.

Norms

Respect

Open

Engagement

One Team

Strategic priority



Strategic focus on USA



Efficient processes



Expansion within new market segments and new applications



Commercialize research to new business opportunities

Business model



Revenue from implants

(License/Processing/Royalty)



Revenue from products

(Customer Development /Coating Liquid)

Long-term growth and profitability goals

Annual growth

> 25 % CAGR

EBITDA margin

> 40 %

Board of Directors and Management

Board of Directors



Tommy H. Karlsson

Chairman of the Board since 2018

Born: 1946

Education: M.Sc. in Business Administration, Uppsala University

Background: -

Other assignments: Jurk Group AB

Shares and stock options in Promimic AB: 85 000 shares and 0 stock options

Independence in relation to the company: Yes

Independence in relation to major shareholders: Yes



Pehr Abrahamsson

Board member since 2021

Born: 1967

Education: M.Sc. in Business Administration, Lund University and Executive Program, Harvard Business School

Background: Director, Stryker Medical

Other assignments: -

Shares and stock options in Promimic AB: 1 875 shares and 0 stock options

Independence in relation to the company: Yes

Independence in relation to major shareholders: Yes



Helena Brisby

Board member since 2021

Born: 1965

Education: Medical degree, Linköping University and doctorate in medicine, Gothenburg University

Background: Professor and Chief Physician in Orthopedics at the University of Gothenburg/Sahlgrenska University Hospital

Other assignments: Dynaspine Diagnostics AB, Inventra AB and board member of research foundations: Felix Neubergs Foundation and The International Society for Study of the Lumbar Spine

Shares and stock options in Promimic AB: 1 875 shares and 0 stock options

Independence in relation to the company: Yes

Independence in relation to major shareholders: Yes

Board of Directors



Johan Dighed

Board member since 2021

Born: 1973

Education: B.Sc. in Law, Lund University

Background: Deputy CEO and general counsel at Karolinska Development AB

Other assignments: KDev Investments AB, KDev Invest Consulting AB, KCIF Fund Management, AnaCardio AB, AnaCardio R&D AB, AnaCardio Holding AB, KD Incentive AB, Modus Therapeutics AB, Modus Therapeutics Holding AB, PharmNovo AB

Shares and stock options in Promimic AB: 0 shares and 0 stock options

Independence in relation to the company: Yes

Independence in relation to major shareholders: No



Johan Holmström

Board member since 2024

Born: 1970

Education: Civilekonom, Handelshögskolan, Göteborgs Universitet


Background: Chief Commercial Officer (CCO), XVIVO Perfusion AB (publ)

Other assignments: -

Shares and stock options in Promimic AB (publ): 0 shares and 0 options

Independence in relation to the company: Yes

Independence in relation to major shareholders: Yes



Pia Renaudin

Board member since 2025

Born: 1967

Education: MBA Handelshögskolan, Göteborgs Universitet, and INSEAD

Background: CEO SciBase AB (Publ.)

Other assignments: Board member of Suturion AB

Shares and stock options in Promimic AB (publ): 0 shares and 0 options

Independence in relation to the company: Yes

Independence in relation to major shareholders: Yes

Management



Magnus Larsson

CEO since 2017

Born: 1963

Education: B.Sc. in business administration, University of Lund

Background: Magnus Larsson has extensive experience from leading positions in pharmaceuticals and medical technology in both small and large organizations, e.g. Johnson & Johnson Pharma and Nobel Biocare. Before Magnus joined Promimic, he was Director of Global Market Development at DentsplySirona Implants.

Shares in Promimic AB: 104,951 shares (privately and related parties)

Stock options in Promimic AB: 5,000 stock options



Ulf Brogren

CCO since 2019, joined 2008

Born: 1973

Education: B.Sc. University of Gothenburg, and journalist

Background: Ulf Brogren has for almost fifteen years held various leading positions within Promimic AB, such as CEO and board member. Prior to that, Ulf was Marketing Director and Investment Manager at Chalmers Innovation and worked with advice and board work in roughly 10 start-up companies.

Shares in Promimic AB: 28,382 shares

Stock options in Promimic AB: 9,000 stock options



Heidi Bader

CFO since 2023

Born: 1981

Education: M.Sc. in Management and B.Sc. in Accounting from the School of Economics at the University of Gothenburg

Background: Heidi Bader has most recently worked as CFO for FlexQube AB and has many years of experience in leading finance positions in the transport industry. She also has experience as Operations Manager in the consultant and recruitment industry.

Shares in Promimic AB: 6 107 shares (privately and related parties)

Stock options in Promimic AB: 5,000 stock options



Per Kjellin

CTO since 2006

Born: 1972

Education: Doctoral degree in Materials Science and Surface Chemistry, Chalmers University of Technology

Background: Per Kjellin is one of the company's founders and has a PhD in Materials and Surface Chemistry from Chalmers, with a focus on nanomaterials. Per has published a number of articles in the field from his research. He is behind all granted and applied patents for the company.

Shares in Promimic AB: 480,102 shares (privately and through company)

Stock options in Promimic AB: 1,000 stock options



Chris Whitfield

President Promimic Inc since 2021, joined 2019

Born: 1967

Education: B.Sc. in Business Administration

Background: Chris Whitfield has solid experience in the medical technology industry and has had leading roles such as CCO for Ametica and Sales and Marketing Director for Pioneer Surgical.

Shares in Promimic AB: 13,730 shares (privately and through company)

Stock options in Promimic AB: 0 stock options

Report of the Board of Director's

The board and managing director of Promimic AB (publ), 556657-7754, hereby submit the annual report for the financial year 2024.

The annual report is prepared in Swedish kronor, SEK, and is mainly presented in thousands

Operations

Promimic AB (publ) is a biomaterials company that manufactures, markets and sells solutions for improved osseointegration to leading companies in the markets for orthopedic and dental implants. The company's main product is HA^{nano} Surface, which means that the surface of the implants mimics the bone, which facilitates the healing process and improves the anchoring of the implants in the bone. The

largest market is the United States. Other important markets are Brazil and Europe.

Promimic AB (publ) is based in Västra Götaland, Mölndal, with offices in GoCo Health Innovation City.

Organizational structure

Promimic group consists of the parent company Promimic AB, a wholly owned subsidiary, Promimic U.S. Inc., USA and 60 percent of Nano Processing Inc (NPI), USA. Promimic AB is the head office and owns all intellectual property rights. Promimic U.S. Inc is a sales company for the American market. NPI is a company that processes implants for the American market.

Multi-year overview

TSEK	Group					Parent Company				
	2025	2024	2023	2022	2021	2025	2024	2023	2022	2021
Net sales	44,420	43,976	37,070	16,214	8,067	40,711	32,924	24,020	13,464	8,067
Profit/loss before tax	-7,594	-7,112	-7,818	-15,388	-15,050	-11,219	-11,962	-12,578	-16,918	-15,266
Total assets	75,711	88,067	92,875	92,774	32,163	80,147	92,575	101,360	104,394	31,544
Return on equity	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg
Operating margin	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg
Equity ratio**) (%)	78	79	83	88	70	80	81	85	89	70
Cashflow**) (%)	250	320	398	607	202	190	275	373	590	197

*) For definitions see Note 1.



Significant events in 2025

- In April 10, the company's Annual Report for 2024 was published.
- On April 17, the company convened the Annual General Meeting to be held on May 22, 2025.
- On April 23, the company announced a strategic collaboration agreement with Lincotek.
- On May 5, the company announced an expanded collaboration with Curiteva.
- On May 15, the company presented strategic business initiatives for growth during the first quarter.
- On May 22, the company held its Annual General Meeting at GoCo Health Innovation City.
- On August 15, the company announced a change of Certified Adviser to Tapper Partners AB.
- On August 22, the company reported a record number of new customers during the second quarter.
- On October 14, the Nomination Committee ahead of the 2026 Annual General Meeting was appointed and consists of the following members: **Lars Kristensson** (appointed by K-Svets Venture AB), **Mathias Frenzel** (appointed by Kdev Investments AB), **Louise Brudö** (appointed by Chalmers Ventures AB), and **Jonas Eixmann** (appointed by Andra AP-fonden).
- On November 19, the company reported its strongest quarter to date, with 21% growth and five new approvals during Q3 2025.



Quality Management System

Promimic AB (publ) conducts quality work in accordance with ISO 13485:2016.

Risk and uncertainties

The board regularly assesses which risks the company has and which measures are required to reduce them. For a complete account of all the company's risks, refer to the company's published prospectus as of April 2022. The main risks related to Promimic's operations and industry include, among other things:

Business, operational and industry-specific risks

Dependence on qualified personnel

The company has a small organization and its success is largely dependent on the competence and experience that the company management and other key personnel possess.

The company's ability to continue developing its operations is dependent on the key personnel's knowledge within the company's field of operations. In the event that Promimic is unable to retain qualified personnel, the company's operations may be negatively affected by reduced development capacity, sales capacity, and competitiveness.

Ability to manage growth

Promimic is in an intensive phase regarding development projects with customers, regulatory processes that the company's customers have together with Promimic, as well as regarding commercialization of the company's products. The

company has had a strong growth in the number of development projects in recent years. During 2024, the company expects to handle around 20 development projects.

In addition, the company is facing an expansion phase in the USA, which requires the company to allocate significant resources from the company's management and operations. In line with a growing business, the business needs to expand through increased staffing and the implementation of effective planning and management processes.

This requires sufficient financial room for maneuver to manage the company's intended growth and carry out its expansion phase.

Dependence on large customers

In the relatively early commercialization phase that the company is in, the company is dependent on a few customers. Should any of these companies cancel the collaboration, it would have a negative effect on the company's sales.

External risks

Uncertainty in the global environment has increased, and market conditions in the United States fluctuate from time to time due to changes in tariff rates. Our business model is primarily based on customers licensing our technology and on our processing of implants in the United States. However, we also have customers outside the U.S. who export implants to the U.S. market. The only product we sell directly that is shipped to the United States is our coating liquid, and there is uncertainty as to whether this product will be subject to tariffs or not.

Financial risks

The company has a negative cash flow. The new share issue of 80 MSEK, before issue costs, that was done in April 2022, in connection with the listing on the Nasdaq First North Growth Market, is expected by management and the Board of Director's to be sufficient for the implementation of the company's business plan up until positive cash flow.

Currency risk

Promimic's income is mainly in US dollars and to some extent in Brazilian reals and in Euros. The costs are mainly in SEK and partly in USD. The company has therefore a net currency risk exposure mainly in USD. The company can secure net flows in USD of up to 12 months with between 50-75 percent.

Legal and regulatory risks

Registration and regulatory requirements

Every implant marketed by Promimic's customers needs to be approved by the relevant regulatory authorities. If Promimic's customers fail to successfully put their applications through the review processes by for example, the FDA or EMA, it would impair the company's future earning capacity and thus the company's financial position.

Economic development in brief during the financial year

Group

Revenue

Net sales amounted to 44,420 TSEK (43,976), an increase of 1 percent compared to the previous year.

Total revenue amounted to 52,733 TSEK (49,360) which was an increase of 7 percent. Balanced development costs of 6,637 TSEK (4,932) relate to the development of a new product for integration into soft tissue, a new product with a ceramic surface and studies regarding the infection prevention effect. Also included in other operating income are both realized and unrealized currency gains amounting to 1,676 TSEK (451).

Earnings

Operating income amounted to -7,700 TSEK (-8,324), an improvement of 624 TSEK. Other external costs decreased with 4,387 TSEK which is partly due to less purchases to the lab but also to the new business model where cost for processing are recognized as cost of goods. Other operating expenses amounted to -1,803 TSEK (-942).

Financial income included interest income of 740 TSEK (957) and realized and unrealized exchange rate gains amounted to 214 TSEK (-67). Financial costs amounted to -859 TSEK (320).

Cashflow and financial position

The cash flow from current operations amounted to -4,195 TSEK (-10,363).

The cash flow from investment activities amounted to a total of -8,818 TSEK (-9,991) of which investment in development projects amounted to -6,637 TSEK (-4,932), patent -400 TSEK (-1,717) and lab equipment for the new premises at GoCo Helath Innovation City and NPI -1,781 TSEK (-3,341).

Cash flow from financing activities was 0 TSEK (5,184).

The group's cash and cash equivalents at the end of the period amounted to 20,630 TSEK (35,765).

Parent Company

Revenue and earnings

Total operating income amounted to 49,023 TSEK (38,307), an increase of 28 percent, excluding the new business model 9 percent.

Operating profit amounted to -10,809 TSEK (-12,934).

Cash

Cash and cash equivalents at the end of the period amounted to 11,660 TSEK (27,360).

The share and owners

Promimic's share has been listed on Nasdaq First North Growth Market since April 29, 2022 under the ticker PRO.

The share capital amounts to SEK 1,889,232.60 for a total of 18,892,326 shares with a quota value of 0.1 SEK.

The shares are registered with Euroclear Sweden AB.

Shareholders	Shares*	Share (%)
K-Svets Venture AB	7,218,840	38.21 %
Kdev Investments AB	2,323,920	12.30%
Avanza Pension	1,317,602	6.97%
Chalmers Ventures AB	1,238,510	6.56%
Andra AP-fonden	1,084,690	5.74%
Riepen LLC	1,035,836	5.48%
FSG Fund II AB	887,678	4.70%
Swedbank Robur Ny Teknik	622,000	3.29%
Per Kjellin and company	480,102	2.54%
Martin Andersson	374,430	1.98%
Marinvest Holding AB	312,500	1.65%
Schroders Investment management	250,000	1.32 %
Others 795	1,746,218	9.24 %
TOTAL	18,892,326	100.00%

*) Source: Euroclear December 31, 2025

Adviser

Tapper Partners AB is the company's Certified Adviser.

Important information about Nasdaq First North

Nasdaq First North Growth Market is an alternative trading platform operated by an organization within the NASDAQ Stockholm Group. Companies on the Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead, they follow a less comprehensive set of rules and regulations tailored to small growth companies. The risk of investing in a company on the Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares that are sold and bought on the Nasdaq First North Growth Market have a certified advisor who checks that the rules are followed. Nasdaq First North Growth Market approves a company's application for a trading license.

Option program

Currently, the company has one option program of 36,250 options from 2024, that expire in 2027.

2024-T04

At the extraordinary general meeting on May 22, 2024, it was decided to issue 57,500 warrants with the right for employees of the company to subscribe. The options have a term of three years and the exercise price is 64 SEK.

Data per aktie

	2025	2024
Average number of shares before dilution	18,892,326	18,774,826
Average number of shares after dilution	18,926,076	18,910,451
Number of shares before dilution at year-end	18,892,326	18,892,326
Number of shares after dilution at year-end	18,926,076	18,928,576
Equity per share before dilution	3.13	3.70
Equity per share after dilution	3.12	3.69
Earnings per share before and after dilution	-0.46	-0.67

Future dividends

Future dividends are dependent on a number of factors. Promimic is a growth company where generated profits are planned to be set aside for the development of the business. No share dividend is therefore planned for the coming years.

Proposed distribution of profits

The following funds in the Parent Company (TSEK) are at the disposal of the Annual General Meeting: -163,072,518

Share premium reserve 218,261,723

Profit/loss for the year -11,219,830

43,969,375

The Board of Director's proposes

the following amount to be carried forward 43,969,375

43,969,375

Regarding the company's results and position in general, reference is made to the subsequent profit and loss statements and accompanying notes.

Balance sheet and income statement will be determined at the ordinary general meeting on May 21, 2026.

Financial Reports

Income Statement | Group

TSEK	2025 Jan-Dec	2024 Jan-Dec
Revenue		
Net sales	44,420	43,976
Own development	6,637	4,932
Other income	2 1,676	451
Total revenue	52,733	49,360
Operational expenses		
Cost of goods	-6,854	-923
Other external expenses	3 -18,628	-23,015
Personnel expenses	4 -28,380	-27,725
Depreciation of tangible and intangible assets	-4,768	-5,079
Other external expenses	-1,803	-942
Total operating costs	-60,433	-57,684
Operating income (EBIT)	-7,700	-8,324
Financial items		
Financial income and similar items	964	892
Interest expenses and similar items	-859	320
Total financial items	105	1,212
Profit/loss before tax	-7,594	-7,112
Income taxes	-1,159	-5,438
Income for the period	-8,754	-12,550



Balance Sheet | Group

TSEK	12/31/2025	12/31/2024	TSEK	12/31/2025	12/31/2024		
ASSETS			EQUITY AND LIABILITIES				
Fixed assets			EQUITY				
Intangible fixed assets			Capital stock	1,889	1,889		
Capitalized development expenses	5	16,901	11,202	204,434	204,434		
Patent	6	4,555	5,088	-147,216	-136,409		
Goodwill	7	1,418	2,314				
Total intangible fixed assets		22,874	18,604	59,107	69,914		
Tangible fixed assets			Current liabilities				
Machinery and other technical facilities	8	5,741	6,301	Accounts payable	3,400	4,717	
Equipment and installations	9	5,016	4,309	Liabilities to credit institutions	0	0	
Total tangible fixed assets		10,757	10,610	Current tax liability	240	774	
Financial assets			Other current liabilities	885	275		
Deferred tax claim	10	0	0	Accrued expenses and deferred income	12	12,079	12,387
Total financial assets		0	0	Total current liabilities	16,605	18,153	
Total fixed assets		33,631	29,214	TOTAL EQUITY AND LIABILITIES	75,711	88,067	
Current assets							
Inventory							
Raw materials and consumables		564	778				
Total inventory		564	778				
Current receivables							
Accounts receivables		12,366	14,797				
Other receivables		859	675				
Tax claim		337	521				
Prepaid expenses and accrued income		7,324	6,317				
Total current receivables		20,886	22,310				
Total cash and cash equivalents		20,630	35,765				
Total current assets		42,080	58,853				
TOTAL ASSETS		75,711	88,067				

Changes in Equity | Group


TSEK	Share capital	Other paid-up capital	Reserves	Profit carried forward	Profit/Loss	Total equity
Opening balance January 1 2024	1,866	199,523	-72	-115,375	-9,222	76,719
Transfer of previous year's results				-9,222	9,222	0
Premium Warrants	24	4,912		249		5,184
Change in exchange rate			560			560
Profit/loss for the period					-12,550	-12,550
Closing balance December 31 2024	1,889	204,434	488	-124,348	-12,550	69,914
Opening balance January 1 2025	1,889	204,434	488	-124,348	-12,550	69,914
Transfer of previous year's results				-12,550	12,550	0
Premium Warrants						0
Exchange rate differences			-2,053			-2,053
Profit/loss for the period					-8,754	-8,754
Closing balance December 31 2025	1,889	204,434	-1,565	-136,898	-8,754	59,107

Cash flow Statement | Group

TSEK	2025 Jan-Dec	2024 Jan-Dec
Operating activities		
Operating income before financial items (EBIT)	-7,700	-8,324
Adjustment for items not included in cash flow	13	5,406
Interest paid/received	713	928
Income tax paid	-1,163	-1,404
Cash flow from operating activities before changes in working capital	-2,744	-2,946
Changes in working capital		
Changes in inventories	214	-448
Changes in operating receivables	-117	-8,966
Changes in operating liabilities	-1,549	1,997
Cash flow from operating activities	-4,195	-10,363
Investment activities		
Investment of intangible fixed assets	-7,037	-6,650
Investment of tangible fixed assets	-1,781	-3,341
Cash flow from investments activities	-8,818	-9,991
Financing activities		
Warrant program	0	5,184
Cash flow from financing activities	0	5 184
CASH FLOW FOR THE PERIOD	-13,013	-15,170
Cash and cash equivalents at the beginning of the period	35,765	50,323
Exchange difference in cash and cash equivalents	-2,121	612
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	20,630	35,765

Income Statement | Parent Company

TSEK	2025 Jan-Dec	2024 Jan-Dec
Revenue		
Net sales	40,711	32,924
Own development	6,637	4,932
Other income	2 1,676	451
Total revenue	49,023	38,307
Operational expenses		
Cost of goods	-10,811	-923
Other external expenses	3 -22,766	-23,659
Personnel expenses	4 -20,707	-21,562
Depreciation of tangible and intangible assets	-3,744	-4,156
Other external expenses	-1,803	-942
Total operating costs	-59,832	-51,241
Operating income (EBIT)	-10,809	-12,934
Financial items		
Financial income and similar items	449	652
Interest expenses and similar items	-859	320
Total financial items	-410	972
Profit/loss before tax	-11,219	-11,962
Income taxes	0	-4,000
Income for the period	-11,219	-15,962



Balance Sheet | Parent Company

TSEK	Not	12/31/2025	12/31/2024	TSEK	12/31/2025	12/31/2024
ASSETS				EQUITY AND LIABILITIES		
Fixed assets				EQUITY		
Intangible fixed assets				Tied-up equity		
Capitalized development expenses	5	16,901	11,202	Share capital	1,889	1,889
Patent	6	4,555	5,088	Fund for development work	17,983	12,438
Total intangible fixed assets		21,455	16,293	Total tied-up equity	19,872	14,327
Tangible fixed assets				Total non-restricted equity		
Machinery and other technical facilities	8	5,271	5,966	Other contributed capital	218,262	218,262
Equipment and installations	9	3,239	3,378	Other equity including profit for the period	-174,292	-157,528
Total tangible fixed assets		8,510	9,344		43,970	60,734
Financial assets				Total equity	63,842	75,062
Shares in group companies	14	18,606	18,606	Current liabilities		
Deferred tax claim	10	0	0	Accounts payable	3,544	4,372
Total financial assets		18,606	18,606	Other current liabilities	698	724
Total fixed assets		48,571	44,243	Accrued expenses and deferred income	12	12,063
Current assets				Total current liabilities	16,305	17,513
Inventory				TOTAL EQUITY AND LIABILITIES	80,147	92,575
Raw materials and consumables		564	778			
Total inventory		564	778			
Current receivables						
Accounts receivables		11,453	12,591			
Receivables group companies		230	275			
Other receivables		859	642			
Tax claim		337	521			
Prepaid expenses and accrued income		6,472	6,165			
Total current receivables		19,352	20,194			
Total cash and cash equivalents	11	11,660	27,360			
Total current assets		31,576	48,332			
TOTAL ASSETS		80,147	92,575			

Changes in Equity | Parent Company

TSEK	Share capital	Fund for development work	Share premium reserve	Profit carried forward	Profit/Loss	Total equity
Opening balance January 1 2024	1,866	7,039	213,350	-123,840	-12,578	85,839
Transfer of previous year's results				-12,578	12,578	0
Net change development fund		5,399		-5,399		0
Premium Warrants	24		4,912	249		5,184
Profit/loss for the period					-15,962	-12,578
Closing balance December 31 2024	1,889	12,438	218,262	-141,566	-15,962	75,062
Opening balance January 1 2025	1,889	12,438	218,262	-141,566	-15,962	75,062
Transfer of previous year's results				-15,962	15,962	0
Net change development fund		5,545		-5,545		0
Premium Warrants						0
Profit/loss for the period					-11,219	-11,219
Closing balance December 31 2025	1,889	17,983	218,262	-163,073	-11,219	63,842

Cash flow Statement | Parent Company

TSEK	2025 Jan-Dec	2024 Jan-Dec
Operating activities		
Operating income before financial items (EBIT)	-10,809	-12,934
Adjustment for items not included in cash flow	13	4,931
Interest paid/received, etc	228	710
Cash flow from operating activities before changes in working capital	-6,199	-7,294
Changes in working capital		
Changes in inventories	214	-447
Changes in operating receivables	201	-8,367
Changes in operating liabilities	-1,208	1,992
Cash flow from operating activities	-6,992	-14,116
Investment activities		
Investment of intangible fixed assets	-7,037	-6,650
Investment of tangible fixed assets	-996	-2,553
Cash flow from investment activities	-8,033	-9,203
Financing activities		
Warrant program	0	5,184
Cash flow from financing activities	0	5,184
CASH FLOW FOR THE PERIOD	-15,027	-18,135
Cash and cash equivalents at the beginning of the period	27,360	45,397
Exchange difference in cash and cash equivalents	-673	98
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	11,660	27,360

Notes

Note 1

Accounting principles

The current financial information has been prepared in accordance with the Annual Accounts Act (1995:1554) and the Swedish Accounting Board's BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3).

Since July 2022, Nano Processing Inc is included, which is considered a joint Venture and is consolidated using the proportionate consolidation method. The principles have not changed compared to previous year.

Assets, provisions and liabilities have been valued at acquisition value unless otherwise stated below.

Intangible assets

Costs for research and development

Expenditure on research, ie. planned and systematic research with the aim of obtaining new scientific or technical knowledge and insight, are reported as costs when they arise.

When accounting for expenses for the development of research results or other knowledge, the cost accounting model is applied, which means that all expenses are booked when they arise.

When reporting expenditure for development the activation model is applied. This means that expenses incurred during the development phase are capitalized when all the conditions below are met:

- It is technically possible to complete the intangible asset so that it can be used or sold.

- The intention is to complete the intangible asset and to use or sell it.
- Conditions exist for using or selling the intangible fixed asset.
- It is likely that the intangible fixed asset will generate future financial benefits.
- There are necessary and adequate technical, financial and other resources to complete the development and to use or sell the intangible assets.
- The expenses attributable to the intangible fixed asset can be calculated reliably.

The acquisition value of an internally generated intangible fixed asset consists of all directly attributable expenses (e.g. materials and salaries).

Depreciation

Depreciation takes place on a linear basis over the asset's estimated useful life. It is ensured that the economic life span exceeds or at least amounts to 10 years. Depreciation is reported as an expense in the income statement.

	Years
<i>Internally generated intangible fixed assets</i>	
Balanced expenditure for development work	10
<i>Acquired intangible assets</i>	
Patents	10

Tangible fixed assets

Tangible fixed assets are reported at acquisition value less accumulated depreciation and any write-downs.

Depreciation

Assets are depreciated on a linear basis over the asset's estimated useful life as it reflects the expected consumption of the asset's future economic benefits. Depreciation is reported as an expense in the income statement.

	Years
Machinery and other technical facilities	5-10
Equipment and installations	3-10

Write-downs – tangible and intangible fixed assets and shares in group companies

At each balance sheet date, it is assessed whether there is any indication that an asset's value is lower than its reported value.

Leasing

All leasing agreements are reported as operational leasing (lease agreements), regardless of whether the agreements are financial or operational. The leasing fee is recognized as a cost linearly over the leasing period.

Foreign currency

Items in foreign currency

Monetary receivables and liabilities in foreign currency have been recalculated at the exchange rate on the balance sheet date.

Note 1 cont'd

Exchange rate differences that arise when settling or recalculating monetary items are reported in the income statement in the accounting year in which they arise, either as an operating item or as a financial item based on the underlying business event.

The company is affected by changes in exchange rates, mainly in relation to the USD and to some extent in relation to the Brazilian real. The company can hedge up to 80 percent of exposed net flows in USD.

Recalculation of foreign operations

Assets and liabilities are converted to the accounting currency at the exchange rate on the balance sheet date. Income and expenses are converted to the average exchange rate. Exchange rate differences that arise during the conversion are reported directly against equity.

Inventory

The inventory is valued at the lower of acquisition value, calculated according to first-in-first-out, and net sales value. In doing so, obsolescence risk has been taken into account. In addition to purchase expenses, the acquisition value also includes expenses for bringing the goods to their current location and condition.

Financial assets and liabilities

Financial assets and liabilities are reported in accordance with chapter 11 of BFNAR 2012:1. Instruments are valued based on acquisition value.

Accounting in and removal from the balance sheet

A financial asset or financial liability is included in the balance sheet when the company becomes a party to the contractual

terms of the instrument. A financial asset is removed from the balance sheet when the contractual right to the cash flow from the asset ends or is settled. The same applies when the risks and benefits associated with the holding have essentially been transferred to another party and the company no longer has control over the financial asset. A financial liability is removed from the balance sheet when the contractual obligation has been fulfilled or terminated.

Valuation of financial assets

Financial assets are valued at acquisition value at the time of first accounting.

Accounts receivable and other receivables that constitute current assets are valued individually at the amount that is estimated to be affected.

Financial fixed assets are valued after the first accounting period at acquisition value with deductions for possible write-downs and with additions for possible revaluations.

Valuation of financial liabilities

Accounts payable and other non-interest-bearing liabilities are valued at accrued cost.

Compensation to employees**Benefits to employees after termination of employment**

In the company, there are exclusively pension plans that are managed as defined contribution plans. There are no other significant agreements that involve compensation after termination of employment other than what falls within the framework of union agreements or common practice for senior executives.

Tax

Tax on the year's profit in the income statement consists of

current tax and deferred tax.

The deferred tax asset is valued at a maximum of the amount that is likely to be recovered based on current and future taxable results. The valuation is reassessed every balance day.

Contingent liabilities

A contingent liability is:

- A possible obligation as a result of occurring events and whose existence will only be confirmed by one or more uncertain future events, which are not entirely within the company's control, occur or fail to occur, or
- An existing obligation as a result of events that have occurred, but which is not recognized as a liability or provision because it is not likely that an outflow of resources will be required to settle the obligation or the size of the obligation cannot be calculated with sufficient reliability.

Contingent liabilities is a summary term for such guarantees, financial commitments and possible obligations that are not included in the balance sheet.

Revenue

The inflow of financial benefits that the company has received or will receive for its own account is reported as income. Revenue is valued at the fair value of what has been received or will be received, less discounts.

Sale of goods

Sale of goods is recognized when the company has transferred to the buyer the essential risks and benefits associated with ownership, normally when the customer has an item in his possession.

Revenues from the sale of goods that do not have any significant service obligations are reported upon delivery.

Note 1, cont'd**Interest and royalty**

Income is recognized when the financial benefits associated with the transaction are likely to accrue to the company and when the income can be calculated reliably.

Royalty is accrued in accordance with the financial meaning of the agreement.

Contribution

A public grant that is not associated with requirements for future performance is reported when the conditions for receiving the grant have been met. A public grant that is linked to requirements for future performance is recognized as revenue when the performance is performed. If the contribution has been received before the conditions for reporting it as income have been met, the contribution is reported as a liability.

Consolidation**Subsidiary**

Subsidiaries are companies in which the parent company directly or indirectly holds more than 50 percent of the voting rights or otherwise has a controlling influence. Determining influence means a right to shape a company's financial and operational strategies in order to obtain financial benefits.

Promimic holds 60 percent of the shares in Nano Processing Inc., which is consolidated in accordance with the proportionate consolidation method as it is a Joint Venture.

Accounting principles in the parent company

The accounting principles in the parent company are consistent with the above stated accounting principles in the consolidated accounts.

Cashflow analysis

The cash flow analysis has been prepared according to the indirect method.

Definitions

Solidity: Adjusted equity as a percentage of total assets

Cash liquidity: Current assets excluding inventory as a percentage of current liabilities

Average number of shares: Number of shares at the end of each quarter divided by the number of quarters (five)

Note 2**Other income**

	Group/Parent company	
Other operating income split by type of income	2025	2024
Grants received	100	0
Exchange rate gains	1,576	451
Total operating income	1,676	451

	Group/Parent company	
Other operating income split by type of income	2025	2024
Grants received	100	0
Exchange rate gains	1,576	451
Total operating income	1,676	451

Note 3**Auditors**

	Group/Parent company	
Remuneration and expense reimbursements for auditors	2025	2024
Audit	275	240
Advice	15	0
Total	290	240

	Group/Parent company	
Remuneration and expense reimbursements for auditors	2025	2024
Audit	275	240
Advice	15	0
Total	290	240

Note 4

Personnel

The average number of employees is based on hours paid by the company in relation to normal working hours.

	Number		Of whom men, percent	
	2025	2024	2025	2024
Average number of employees				
Parent company	16.5	17	47	47
Subsidiaries	3	2	100	100
Total average number of employees	19	19		

	Number		Of whom men, percent	
	2025	2024	2025	2024
Gender distribution in Board and Management				
Parent company	10	10	73	80
Subsidiaries	1	1	100	100

TSEK	Salaries and remuneration, etc		Social security contributions	
	2025	2024	2025	2024
Total salaries, remuneration and social securities				
Parent company	-14,228	-14,428	-4,185	-4,473
(of which pension costs)	(-1,674)	(-1,571)	(-406)	(-381)
Subsidiaries	-7,647	-5,892	-394	-304
(of which pension costs)	(-205)	(-158)	-	-
Board	-1,100	-1,250	-290	-290
Total salaries, remuneration and social securities	-22,975	-21,570	-4,869	-5,067

Note 5

Expenditures brought forward for development work

	Group/Parent company	
	12/31/2025	12/31/2024
Opening cost	19,428	14,496
Cost for the year	6,637	4,932
Outgoing acquisition value	26,066	19,428
Opening depreciation	-8,226	-7,089
Depreciations in the year	-939	-1,137
Outgoing depreciations	-9,165	-8,226
Outgoing balance	16,901	11,202

Note 6

Patents

	Group/Parent company	
	12/31/2025	12/31/2024
Opening cost	13,778	12,060
Cost for the year	400	1,718
Outgoing acquisition value	14,178	13,778
Opening depreciation	-8,690	-7,312
Depreciations in the year	-933	-1,378
Outgoing depreciations	-9,623	-8,690
Outgoing balance	4,555	5,088

Note 7

Goodwill

	Group	
	12/31/2025	12/31/2024
Opening acquisition value	4,479	4,479
Acquisitions in the year	0	0
Outgoing acquisition value	4,479	4,479
Opening depreciation	-2,165	-1,269
Depreciations in the year	-896	-896
Outgoing depreciations	-3,061	-2,165
Outgoing balance	1,418	2,314

Note 8

Machinery and other technical facilities

	Group	
	12/31/2025	12/31/2024
Opening acquisition value	9,089	7,810
Acquired machinery		
Purchases	995	1,279
Outgoing acquisition value	10,084	9,089
Opening depreciation	-2,786	-1,458
Depreciations in the year	-1,557	-1,329
Outgoing depreciations	-4,282	-2,786
Outgoing balance	5,741	6,301

	Parent company	
	12/31/2025	12/31/2024
Opening acquisition value	8,719	7,517
Purchases	717	1,202
Outgoing acquisition value	9,436	8,719
Opening depreciation	-2,754	-1,444
Depreciations in the year	-1,412	-1,310
Outgoing depreciations	-4,166	-2,754
Outgoing balance	5,271	5,966

Note 9

Equipment and installations

	Group	
	12/31/2025	12/31/2024
Opening acquisition value	4,862	2,801
Acquired equipment and installations		
Purchases	786	2,062
Outgoing acquisition value	5,648	4,862
Opening depreciation	-553	-215
Depreciation in the year	-78	-338
Outgoing depreciation	-632	-553
Outgoing balance	5,016	4,309

	Parent company	
	12/31/2025	12/31/2024
Opening acquisition value	3,766	2,415
Purchases	279	1,352
Outgoing acquisition value	4,045	3,766
Opening depreciation	-390	-59
Scrapping	0	0
Depreciations in the year	-417	-331
Outgoing depreciations	-808	-390
Outgoing balance	3,239	3,378

Note 10

Deferred tax

	Group/Parent company	
	12/31/2025	12/31/2024
Opening deferred tax claim	0	4,000
Reversal of loss carry forwards	0	-4,000
Outgoing deferred tax asset	0	0

Note 11

Cash and cash equivalents

	Group	
	12/31/2025	12/31/2024
Available cash bank accounts	20,630	35,765
Locked funds	0	0
Total	20,630	35,765

	Parent company	
	12/31/2025	12/31/2024
Available cash bank accounts	11,660	27,360
Locked funds	0	0
Total	11,660	27,360

Note 12

Accrued costs and prepaid income

	Group	
	12/31/2025	12/31/2024
Prepaid income	7,772	7,386
Salaries and social security contributions	3,678	3,895
Other accrued costs	629	1,106
Total	12,079	12,387

	Parent company	
	12/31/2025	12/31/2024
Prepaid income	7,772	7,386
Salaries and social security contributions	3,678	3,895
Other accrued costs	613	1,136
Total	12,063	12,417

Note 13

Adjustments for non cash items

	Group	
	2025	2024
Depreciations according to income statement	4,768	5,079
Unrealized currency effects	638	775
Total	5,406	5,854

	Parent company	
	2025	2024
Depreciations	3,744	4,156
Unrealized currency effects	638	775
Total	4,382	4,931

Note 15

Significant events after the end of the financial year

No significant events occurred after the end of the reporting period.

Note 14

Shares in group companies

Group companies	CIN	Registered office	Share/Percent
Promimic U.S. Incorporated	35-2569829	Delaware, USA	100
Nano Processing Inc	88-3098397	Indiana, USA	60

TSEK

Book value per December 31, 2025	18,606
----------------------------------	--------

Signatures

The content of the annual report and consolidated financial statement was finalized and approved for issuance by the board of directors and the managing director on March 26, 2026

Möln dal April 9, 2026

Tommy H. Karlsson

Chairman of the Board

Johan Dighed

Member of the Board

Pehr Abrahamsson

Member of the Board

Johan Holmström

Member of the Board

Magnus Larsson

CEO

Helena Brisby

Member of the Board

Pia Renaudin

Member of the Board

Our audit report was submitted April 9, 2026

KPMG AB

Johan Kratz

Certified Public Accountant

Audit Report

To the General Meeting of Promimic AB (publ),
corp.id 556657-7754

Report on the annual accounts and consolidated accounts

Opinions

We have audited the annual accounts and consolidated accounts of Promimic AB (publ) for the year 2025. The annual accounts and consolidated accounts of the company are included on pages 17-34 in this document.

In our opinion, the annual accounts and consolidated accounts have been prepared in accordance with the Annual Accounts Act, and present fairly, in all material respects, the financial position of the parent company and the group as of 31 December 2025 and their financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and the group.

Basis for opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the

group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Other information than the annual accounts and consolidated accounts

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1-16 and 38-41. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts The Board of Directors and the Managing Director are responsible for the assessment of the company's and the group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intend to liquidate the company, to cease operations, or has no realistic alternative but to do so.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered

material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts and consolidated accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of the company's internal control relevant to our audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. We evaluate the appropriateness of the accounting principles used and the reasonableness of the board's and managing director's estimates in the accounting and associated information.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors and the Managing Director.
- Conclude on the appropriateness of the Board of Directors'

and the Managing Director's, use of the going concern basis of accounting in preparing the annual accounts and consolidated accounts. We also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's and the group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts and consolidated accounts or, if such disclosures are inadequate, to modify our opinion about the annual accounts and consolidated accounts. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a company and a group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts and consolidated accounts, including the disclosures, and whether the annual accounts and consolidated accounts represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business units within the group as a basis for forming an opinion on the consolidated accounts. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our opinions.

We must inform the Board of Directors of, among other

matters, the planned scope and timing of the audit. We must also inform of significant audit findings during our audit, including any significant deficiencies in internal control that we identified.

Report on other legal and regulatory requirements

Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of Promimic AB (publ) for the year 2025 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

Basis for Opinions

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's and the group's type of operations, size and risks place on the size of the parent company's and the group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner.

The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

Auditor's responsibility

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or

the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, we exercise professional judgment and maintain professional scepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on our professional judgment with starting point in risk and materiality. This means that we focus the examination on such actions, areas and relationships that are material for the operations and where

deviations and violations would have particular importance for the company's situation. We examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to our opinion concerning discharge from liability. As a basis for our opinion on the Board of Directors' proposed appropriations of the company's profit or loss we examined whether the proposal is in accordance with the Companies Act.

Göteborg April 9, 2026

KPMG AB

Johan Kratz, Certified Public Accountant

Governance Report

Promimic's corporate governance describes how the owners, through the general meeting, and the board govern the company and ensure that the CEO and company management create value and manage the risks in the business.

Corporate governance

The governance of Promimic is based on the Swedish Companies Act, the Articles of Association, Nasdaq First North Growth Market's regulations, internal rules and regulations, as well as other applicable Swedish and foreign laws and regulations.

The purpose of the company's operations shall be to develop and sell products to implant companies as well as to conduct other compatible activities.

Internal control

The Board's responsibility for internal control is regulated in the Limited Liability Companies Act and the Annual Accounts Act - which contain requirements that information about the most important elements of Promimic's system for internal control and risk management in connection with the financial reporting must be included in the corporate governance report each year.

Among other things, the Board must ensure that Promimic has good internal control and formalized routines that ensure that established principles for financial reporting and internal control are adhered to and that there are appropriate systems for monitoring and controlling the company's operations and the risks that Promimic and its operations are associated with.

The overall purpose of internal control is to reasonably ensure that the company's operational strategies and goals are followed up and that the owners' investment is protected.

The internal control must further ensure that the external financial reporting is reliable with reasonable certainty and prepared in accordance with good accounting practice, that applicable laws and regulations are followed and that requirements for listed companies are complied with.

Monitoring environment

The Board has the overall responsibility for the internal control regarding the financial reporting. In order to create and maintain a functioning control environment, the Board has adopted a number of policies and governing documents that regulate the financial reporting.

These mainly consist of the Board's rules of procedure, CEO instructions and instructions for financial reporting. The Board has also adopted a special financial policy, information policy and an insider policy. The Board continuously monitors the company's financial position and the effectiveness of the company's internal control and risk management, and keeps itself informed of the audit of the annual report and consolidated financial statements. Furthermore, the Board reviews and monitors the auditor's impartiality and independence. The Board also receives reports from Promimic's auditor.

Management and follow-up

Ongoing follow-up of profit outcomes take place at group level against budget and forecasts. Reporting takes place to the managing director and Board. According to the Board's instructions to the CEO, the company's auditors must report

their work directly to the Board at least once a year.

Information och communication

The company has information and communication channels that aim to promote the accuracy of the financial reporting and enable reporting and feedback from the business to the board and management, for example by making governing documents in the form of internal policies, guidelines and instructions regarding the financial reporting available and known to affected employees.

The company has also drawn up policy and instructions with the aim of informing employees and other stakeholders within Promimic about the laws that are applicable regarding the company's disclosure of information and the special requirements for people who are active in a listed company in situations such as the handling of insider information. In connection with this, Promimic has established routines for handling and limiting the dissemination of information that has not yet been published, so-called deferred publication.

The Board has adopted a communication policy and insider policy that regulate the group's disclosure of information.

Risk assessment

The Board receives additional information about risk management, internal control and financial reporting from the auditor at board meetings with the auditor present.

Monitoring activities

Control activities limit identified risks and ensure accurate and reliable financial reporting. The Board is responsible for the internal control and follow-up of the company management.

This takes place through both internal and external control activities as well as through review and follow-up of the company's governing documents.

An important part of Promimic's control activities are standardized reporting routines as well as clear and documented work arrangements and division of responsibilities.

Need for internal auditing

The effectiveness of internal auditing is largely dependent on the company's organizational structure and the size of the organization. Promimic has a relatively small organization where finance, economics and other administration are managed from the company's office in Mölndal. Follow-up of results and balance is done monthly by the various functions within the company as well as by the company's management and board. All in all, this means that it is not considered justified to have a special unit for internal audit.

Shareholders

The Promimic group consists of two wholly owned companies and one partially owned company. Parent company in the group is the Swedish public limited company Promimic AB (publ), whose shares are listed on the Nasdaq First North Growth Market. The share capital in Promimic is represented by ordinary shares. The number of shares amounted to 18,892,326 with equal rights, corresponding to a quota value of 10 öre. As of December 31, 2025, the number of shareholders amounted to approximately 800. For further information on ownership structure, trading and price development, see page [20](#) of the annual report. The larger main shareholders in

Promimic exercise an active ownership role. The board and group management control a total of 66.2 percent of capital and votes in the company. The articles of association do not contain a reservation on voting rights limitation.

General Meeting

Shareholders' right to decide in Promimic's affairs is exercised through the highest decision-making body, the Annual General Meeting or extraordinary General Meeting. The meeting decides, for example, on changes to the Articles of Association, Board and auditor elections, determination of the profit and loss account, discharge of liability for the Board and the CEO, and disposition of profit or loss.

According to Promimic's Articles of Association, notices to the general meeting must be given by advertising in Post- och Inrikes Tidningar and by making the notice available on the company's website as well as announcing in Dagens Industri.

Voting rights accrue to shareholders who, according to the notice's instructions, have registered for the meeting and who are included in the general meeting share register that is produced before the meeting.

Right to attend

In order to participate in the general meeting, shareholders must register with Promimic no later than the day stated in the notice to the general meeting. This day must not be Sunday, another public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year's Eve and not fall earlier than the fifth weekday before the meeting.

Initiatives from shareholders

Shareholders who wish to have a matter dealt with at the general meeting must submit a written request to the company's Board no later than four weeks before the general meeting.

Annual General Meeting 2025

The 2025 Annual General Meeting was held on May 22, physically in Mölndal. Altogether, 62.4 percent of the total number of shares and votes were present. The accounts for 2024 were approved and the board members and CEO were granted discharge. Decisions were also made on the election of Board members, Chairman of the board and auditor, as well as fees for the board and auditor.

Annual General Meeting 2026

The Annual General Meeting will be held physically in Mölndal on May 21, 2026.

Nomination Committee

The general meeting has decided on a principle for the appointment of the selection committee. The election committee shall consist of representatives from the four largest shareholders in terms of votes listed in the by Euroclear Sweden maintained the share register as of the last banking day in August. The chairman of the board must convene the first the meeting. Board members, CEO or others senior executives in the company must not be members of the selection committee.

The following people are part of the election committee:

- Lars Kristensson, appointed by K-Svets Venture AB
- Mathias Frenzel, appointed by Kdev Investments AB
- Louise Brudö, appointed by Chalmers Ventures AB
- Jonas Eixmann, appointed by Andra AP-Fonden

The appointment has taken place in accordance with the instructions regarding principles for appointment to the Nomination Committee that were established at the annual general meeting of Promimic AB on May 22, 2025. The shareholders who have appointed the members of the nomination committee represented a total of roughly 63 percent of all shares in the company on August 31, 2025.

The nomination committee's task is to prepare and present proposals before the Annual General meeting regarding the number of Board members to be elected by the general meeting, election of the Chairman and other members of the board, board fees, election of the chairman at the annual general meeting, election of auditors (if applicable) and proposals for rules for appointment of the nomination committee before the upcoming annual general meeting.

Board of Directors

After the general meeting, the Board is Promimic's highest decision-making body. It is the Board that is responsible for the company's organization and the management of the company's affairs, for example by establishing goals and strategy, ensuring routines and systems for following up on the established goals, continuously assessing Promimic's financial situation and evaluating the operational manage-

ment. It is also the board's responsibility to ensure that correct information is provided to the company's shareholders, that the company complies with laws and regulations, and that the company develops and implements internal policies and ethical guidelines.

The board also appoints Promimic's managing director and determines the salary and other remuneration based on current guidelines.

Composition

The board members are elected annually by the annual general meeting for the period until the next annual general meeting is held. According to the articles of association, the board must consist of a minimum of four and a maximum of 10 members without deputies.

In 2025, the board consisted of six members who are elected for one year by the annual general meeting. Currently, the company's board consists of Tommy Karlsson as Chairman of the Board and members Pehr Abrahamsson, Helena Brisby, Johan Dighed, Johan Holmström and Pia Renaudin..

CEO Magnus Larsson is not part of the board, but participates as presenter at all meetings. The members of the Board are presented in more detail on pages [14-15](#).

Chairman

The Chairman of the Board leads the board meetings. Every question concerning the company conditions that is referred to the Board must be referred to the Chairman of the Board, who must then ensure that the question is prepared and at a later board meeting presented for decision or as information.

The Chairman's duties also include reviewing and following the board's work, preparing the agenda for board meetings, summarizing the discussions at board meetings, following the management's work and acting as support to the CEO, ensuring that the Board's decisions are implemented, and maintaining regular contact with the Board members between board meetings.

The work

The Board follows a written procedure that is reviewed annually and determined at the constituent board meeting. The rules of procedure regulate, among other things, the board's working methods, duties, decision-making order within the company, the board's meeting schedule, the Chairman's duties and an appropriate distribution of work between the Board and the CEO. Instructions regarding financial reporting and instructions to the CEO are also established in connection with the constituent board meeting. The Board's work is also conducted based on an annual meeting plan that meets the board's need for information. The meeting plan must be designed so that the meetings coincide with the preparation of quarterly reports and financial statements.

The control questions that come to the board are handled by the board as a whole. In addition to the board meetings, the chairman of the board and the CEO have an ongoing dialogue regarding the management of Promimic. The Board meets according to a pre-decided meeting plan and must hold at least six regular board meetings in addition to the constituent meeting between each general meeting.

In addition to these meetings, extra meetings can be arranged. In 2025, the board held 12 minutes-recorded meetings, of which one is a constituent meeting.

Below is a list of the members attendance.

Name	Attendance
Tommy Karlsson	12/12
Pehr Abrahamsson	11/12
Helena Brisby	10/12
Johan Dighed	12/12
Johan Holmström	12/12
Håkan Krook	5/5
Pia Renaudin	7/7

Committees

The board has a remuneration committee. The remuneration committee consists of Tommy Karlsson (chairman of the board) and Pehr Abrahamsson (member of the board). The CEO is the rapporteur in matters that do not affect the CEO terms and conditions. The remuneration committee is tasked with reviewing and making recommendations to the Board regarding the principles for conditions and remuneration for the company's senior executives. The remuneration committee must evaluate the CEO's work annually. Questions concerning the CEO's terms of employment, remuneration and benefits are prepared by the remuneration committee and decided by the board.

In his role, the CEO is subordinate to the board and his main task is to manage Promimic's ongoing management and day-to-day operations. The Board's rules of procedure and the

CEO's instructions show which issues Promimic's board must decide on and which decisions fall on the CEO.

The CEO also prepares reports and necessary decision-making documents for board meetings and is the presenter of the material at board meetings. In addition to the CEO, Promimic has four senior executives, see page [16](#).

Audit

Promimic's auditor examines the annual accounts and annual report as well as the company's ongoing operations and routines in order to then express an opinion on the accounting and the administration of the board and the CEO. The auditor must submit an audit report to the general meeting after each financial year. The company's auditor reports to the board his observations from the review and his assessments of the company's internal control.

At the Annual General Meeting on May 22, 2025, it was decided to re-elect KPMG as auditing firm, with Johan Kratz as Auditor in charge. It was also decided that compensation to the Auditor should be paid according to an approved bill.

Governance Report

To the General Meeting of Promimic AB (publ),
CIN 556657-7754

Tasks and division of responsibilities

It is the board that is responsible for the corporate governance report and that it is prepared in accordance with the Annual Accounts Act.

Focus and scope of the review

Our review is in accordance with FAR's statement RevR16 The auditor's review of the corporate governance report. This means that our review has a different focus and a significantly smaller scope compared to the focus and scope of an audit according to International Standards on Auditing and good auditing practice in Sweden. We believe that this review provides us with sufficient basis for our statements.

Statement

A corporate governance report has been drawn up. Information in accordance with ch. 6 § 6, second paragraph, points 2–6 of the Annual Accounts Act and ch. 7 § 31 second paragraph of the same act are compatible with the other parts of the annual accounts and consolidated accounts and are in accordance with the Annual Accounts Act.

Göteborg April 9, 2026

KPMG AB

Johan Kratz, Certified Public Accountant

Promimic AB (publ) | Orgnr 556657-7754 | info@promimic.com | www.promimic.com

Entreprenörstråket 10, 431 53 Mölndal, Sverige

